Security
Alpha Tau Medical Ltd. Warrant · DRTSW
DRTSWNASDAQWarrantCurrentCIK 1871321Updated Oct 30, 2026
DRTSW price & chart
Loading TradingView…
NASDAQ:DRTSW on TradingView ↗About the company
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| AssetsUSD | 110,954,000Source | 96,048,000Source | 111,206,000Source | — | 105,652,000Source | 86,204,000Source | 107,388,000Source | 120,149,000Source |
| Property, Plant and Equipment, NetUSD | 17,285,000Source | 12,354,000Source | 7,549,000Source | — | 19,661,000Source | 13,934,000Source | 12,798,000Source | 7,471,000Source |
| Current assets: | ||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,703,000Source | 2,763,000Source | 855,000Source | — | 12,202,000Source | 13,724,000Source | 12,657,000Source | 5,836,000Source |
| Assets, CurrentUSD | 85,778,000Source | 75,248,000Source | 96,059,000Source | — | 78,298,000Source | 64,229,000Source | 85,756,000Source | 106,477,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,525,000Source | 1,102,000Source | 1,698,000Source | — | 1,395,000Source | 1,374,000Source | 816,000Source | 1,097,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,428,000Source | 8,009,000Source | 7,157,000Source | — | 7,214,000Source | 7,609,000Source | 8,363,000Source | 5,810,000Source |
| LIABILITIES AND EQUITY | ||||||||
| LiabilitiesUSD | 24,331,000Source | 22,031,000Source | 18,643,000Source | — | 28,553,000Source | 23,538,000Source | 22,913,000Source | 14,492,000Source |
| Stockholders’ equity: | ||||||||
| Additional Paid in CapitalUSD | — | — | 196,045,000Source | — | — | — | 200,234,000Source | 192,259,000Source |
| Retained Earnings (Accumulated Deficit)USD | -166,314,000Source | -131,109,000Source | -103,482,000Source | — | -190,136,000Source | -147,509,000Source | -115,759,000Source | -86,602,000Source |
| Stockholders' Equity Attributable to ParentUSD | 86,623,000Source | 74,017,000Source | 92,563,000Source | 108,268,000Source | 77,099,000Source | 62,666,000Source | 84,475,000Source | 105,657,000Source |
| Additional Paid in Capital, Common StockUSD | 252,937,000Source | 205,126,000Source | — | — | 267,235,000Source | 210,175,000Source | — | — |
| Liabilities and EquityUSD | 110,954,000Source | 96,048,000Source | 111,206,000Source | — | 105,652,000Source | 86,204,000Source | 107,388,000Source | 120,149,000Source |
| Current liabilities: | ||||||||
| Liabilities, CurrentUSD | 8,156,000Source | 6,456,000Source | 5,416,000Source | — | 10,507,000Source | 8,675,000Source | 7,102,000Source | 4,338,000Source |
| Operating Lease, Liability, CurrentUSD | 1,080,000Source | 1,038,000Source | 846,000Source | — | 1,131,000Source | 1,011,000Source | 1,062,000Source | 669,000Source |
| Accounts Payable, CurrentUSD | — | — | 1,789,000Source | — | — | — | 2,566,000Source | 1,423,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,201,000Source | 6,109,000Source | 5,433,000Source | — | 6,243,000Source | 5,964,000Source | 6,604,000Source | 4,524,000Source |
| Additional Financial Items | ||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | 3,784,000Source | 2,615,000Source | 2,236,000Source | 1,276,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 83,253,000Source | 74,146,000Source | — | — | 76,903,000Source | 62,855,000Source | 84,940,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | 1,025,000Source | — | — | — |
| Short-term InvestmentsUSD | 67,996,000Source | 68,268,000Source | 92,672,000Source | — | 60,924,000Source | 45,876,000Source | 69,131,000Source | 98,694,000Source |
| Other Assets, Noncurrent | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 10,617,000Source | 9,916,000Source | 7,926,000Source | 6,748,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | 97,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | -26,681,000Source | -19,783,000Source | -17,958,000Source | -23,879,000Source |
| Cash flows from investing activities: | ||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | -20,588,000Source | 20,768,000Source | 18,682,000Source | -89,936,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | 6,075,000Source | 2,238,000Source | 6,401,000Source | 904,000Source |
| Cash flows from financing activities: | ||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | 45,768,000Source | 25,000Source | 5,297,000Source | 96,905,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | -1,522,000Source | 1,067,000Source | 5,971,000Source | -17,168,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 11,703,000Source | 2,763,000Source | 1,689,000Source | 12,363,000Source | 12,202,000Source | 13,724,000Source | 12,657,000Source | 6,686,000Source |
| Supplemental disclosure of cash flow information: | ||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | 381,000Source | 321,000Source | 52,000Source | 237,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | -21,000Source | 57,000Source | -50,000Source | -258,000Source |
| Additional Financial Items | ||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 10,617,000Source | 9,916,000Source | 7,926,000Source | 6,748,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 83,253,000Source | 74,146,000Source | — | — | 76,903,000Source | 62,855,000Source | 84,940,000Source | — |
| DepreciationUSD | — | — | — | — | 1,232,000Source | 1,102,000Source | 1,074,000Source | 979,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | 106,000Source | — | 413,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | -35,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | 8,363,000Source | 6,673,000Source | 7,332,000Source | 10,272,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | -33,762,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | 33,762,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 121,000Source | 6,000Source | 16,000Source | 20,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | 347,000Source | 303,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | -42,627,000Source | -31,750,000Source | -29,157,000Source | -33,762,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | -218,000Source | 4,298,000Source | 6,539,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | 45,496,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | 272,000Source | 25,000Source | 49,000Source | 27,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -42,288,000Source | -36,042,000Source | -35,680,000Source | -32,136,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -42,506,000Source | -31,744,000Source | -29,141,000Source | -33,742,000Source |
| Income Tax Expense (Benefit)USD | 121,000Source | 6,000Source | 16,000Source | 20,000Source |
| Net Income (Loss) Attributable to ParentUSD | -42,627,000Source | -31,750,000Source | -29,157,000Source | -33,762,000Source |
| Earnings Per Share, BasicUSD per share | -0.53Source | -0.45Source | -0.42Source | -0.53Source |
| Earnings Per Share, DilutedUSD per share | -0.53Source | -0.45Source | -0.42Source | -0.53Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 80,581,440Source | 69,927,566Source | 69,377,922Source | 63,534,875Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 80,581,440Source | 69,927,566Source | 69,377,922Source | 63,534,875Source |
| Interest Expense (non-operating)USD | 347,000Source | 303,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 24,000Source | — | 16,000Source | 20,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | 106,000Source | — | 413,000Source |
| General and Administrative ExpenseUSD | 8,363,000Source | 6,673,000Source | 7,332,000Source | 10,272,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -33,762,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -42,331,000Source | -31,065,000Source | 28,224,000Source | 33,100,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 33,762,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.53Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.53Source |
| Nonoperating Income (Expense)USD | -218,000Source | 4,298,000Source | 6,539,000Source | — |
| Other ExpensesUSD | — | — | — | 16,547Source |
| Research and Development ExpenseUSD | 32,065,000Source | 27,020,000Source | 26,424,000Source | 20,890,000Source |
Offerings
Registration 333-295359
Filing attachments
ea031012301ex99-1.htm · 6-K · 2026-10-29
Exhibit 99.1 Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the 125 largest and most prominent companies on the TASE JERUSALEM, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq and TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced tha…
Read attachment ↗ea030933001ex99-1.htm · 6-K · 2026-10-22
Exhibit 99.1 Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT ® for Pancreatic Cancer Patients in Korea - MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancer…
Read attachment ↗ea030900301ex99-1.htm · 6-K · 2026-10-19
Exhibit 99.1 Alpha Tau Announces FDA Approval to Expand Alpha DaRT ® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting - FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio State University accepted for presentation at the Society for Neuro-Oncology (SNO) 2026 Annual Meeting, marking t…
Read attachment ↗ea030369301ex99-1.htm · 6-K · 2026-08-31
Exhibit 99.1 Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT ® Following Strong Demand and Multiple Expansions - IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is deli…
Read attachment ↗ea030079101ex99-1.htm · 6-K · 2026-08-10
Exhibit 99.1 ALPHA TAU MEDICAL LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Consolidated Balance Sheets F-2-F-3 Consolidated Statements of Operations F-4 Consolidated Statements of Changes in Shareholders’ Equity F-5 Consolidated Statements of Cash Flows F-6 Note…
Read attachment ↗ea030079101ex99-2.htm · 6-K · 2026-08-10
Exhibit 99.2 Operating and Financial Review and Prospects You should read the following discussion together with the unaudited consolidated financial statements as of and for the six months ended June 30, 2025 and 2026 and related notes appearing elsewhere in this Form 6-K, our audited consolidated financial statements and other financial information as of and for the year ended December 31, 2025 appearing in our Annual Report on Form 20-F for the year ended December 31, 2025 (the “Annual Repo…
Read attachment ↗